Oral semaglutide proved nearly as effective as the injectable version for treating obesity, delivering 13.7 percent average weight loss in a 64-week trial.
During a Senate hearing, Britt pressed HHS Secretary Robert F. Kennedy Jr. on NIH reforms, youth mental health challenges, and sustained Head Start funding.